Cargando…

Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial

BACKGROUND: Nafamostat, a serine protease inhibitor, has been used for the treatment of disseminated intravascular coagulation and pancreatitis. In vitro studies and clinical reports suggest its beneficial effect in the treatment of COVID-19 pneumonia. METHODS: This phase 2 open-label, randomised, m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhuravel, Sergey V, Khmelnitskiy, Oleg K, Burlaka, Oleg O, Gritsan, Alexey I, Goloshchekin, Boris M, Kim, Seieun, Hong, Ka Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548051/ https://www.ncbi.nlm.nih.gov/pubmed/34723164 http://dx.doi.org/10.1016/j.eclinm.2021.101169

Ejemplares similares

Mechanisms of NMDA Receptor Inhibition by Sepimostat—Comparison with Nafamostat and Diarylamidine Compounds
por: Zhigulin, Arseniy S., et al.
Publicado: (2023)

Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer
por: Uwagawa, Tadashi, et al.
Publicado: (2022)

Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation
por: Takahashi, Wakana, et al.
Publicado: (2021)

Crystal structure of nafamostat dimesylate
por: Fujii, Isao
Publicado: (2021)

Nafamostat: Hyperkalaemia: case report
Publicado: (2021)

Cardiac arrest caused by nafamostat mesilate
por: Kim, Hyo Shik, et al.
Publicado: (2016)

Clinical efficacy of Nafamostat Mesylate in combination with Favipiravir for COVID-19 pneumonia treatment review article
por: Abduljabbar, Maram H.
Publicado: (2021)

Utility and safety of nafamostat mesilate for anticoagulation in dogs
por: Isayama, Noriko, et al.
Publicado: (2022)

Three cases of treatment with nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy
por: Jang, Sukbin, et al.
Publicado: (2020)

Nafamostat: Off-label use and hyperkalaemia: case report
Publicado: (2020)

Nafamostat mesylate attenuates the pathophysiologic sequelae of neurovascular ischemia
por: Ghali, George Zaki, et al.
Publicado: (2020)

Fatal anaphylaxis Due to Nafamostat Mesylate During Hemodialysis
por: Kim, Joo-Hee, et al.
Publicado: (2021)

Heparin/nafamostat: Bleeding and subcutaneous haematoma: case report
Publicado: (2022)

Heparin/nafamostat: Bleeding, hyperkaelemia and haemothorax: case report
Publicado: (2021)

Cardiopulmonary arrest caused by nafamostat mesylate during hemodialysis
por: Shioya, Nobuki, et al.
Publicado: (2022)

Potential of heparin and nafamostat combination therapy for COVID‐19
por: Asakura, Hidesaku, et al.
Publicado: (2020)

Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics
por: Quinn, Tom M., et al.
Publicado: (2022)

Treatment effect of nafamostat mesylate in patients with COVID-19 pneumonia: study protocol for a randomized controlled trial
por: Moon, Kyunglan, et al.
Publicado: (2021)

Use of Nafamostat Mesilate as an Anticoagulant during Extracorporeal Membrane Oxygenation
por: Han, Sang Jin, et al.
Publicado: (2011)

Retraction: Nafamostat mesylate attenuates the pathophysiologic sequelae of neurovascular ischemia
Publicado: (2021)

Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia
por: Ikeda, Mahoko, et al.
Publicado: (2023)

Cardiac arrest caused by nafamostat mesilate: Kounis syndrome in the dialysis room?
por: Koniari, Ioanna, et al.
Publicado: (2017)

Cytokine expressions of spinal cord injury treated by neurotropin and nafamostat mesylate
por: Sun, Chao, et al.
Publicado: (2021)

Heparin/nafamostat: Oral cavity bleeding and alveolar hemorrhaging: case report
Publicado: (2021)

The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis
por: Kim, Joo Seong, et al.
Publicado: (2022)

Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters
por: Neary, Megan, et al.
Publicado: (2023)

Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance
por: Kitaura, Atsuhiro, et al.
Publicado: (2023)

Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate
por: Iwasaka, Sho, et al.
Publicado: (2020)

Nafamostat for Prophylaxis against Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis Compared with Gabexate
por: Chang, Jae Hyuck, et al.
Publicado: (2009)

Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
por: Hifumi, Toru, et al.
Publicado: (2020)

Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness
por: Yates, Abi G., et al.
Publicado: (2022)

The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation
por: Lee, Jae Ha, et al.
Publicado: (2022)

Status and progress on the ATLAS Phase-II detector upgrades
por: Solovyanov, Oleg
Publicado: (2021)

RAndomized Clinical Trial Of NAfamostat Mesylate, A Potent Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor, in Patients with COVID-19 Pneumonia
por: Seccia, Teresa Maria, et al.
Publicado: (2023)

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma
por: Piper, Edward, et al.
Publicado: (2013)

Validation of Nafamostat Mesilate as an Anticoagulant in Extracorporeal Membrane Oxygenation: A Large-Animal Experiment
por: Han, Sung Joon, et al.
Publicado: (2018)

Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate
por: Osawa, Itsuki, et al.
Publicado: (2020)

Hydroxychloroquine/methylprednisolone/nafamostat: Delayed viral clearance and off label use: case report
Publicado: (2021)

Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians
por: Ji, Hong-Long, et al.
Publicado: (2021)

Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review
por: Hernández-Mitre, María Patricia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sm8brk32cik2fkmpg3a8edgpqo